Pharma Industry

In part two of MJH Life Sciences’ three-part series, experts dissect President Trump’s most-favored nation executive order, warning that its use of tariffs and foreign price benchmarks could upend drug markets and test the limits of federal authority.

Trump’s “most favored nation” drug pricing order could lower costs but raise new challenges for physicians, patients and pharma.

HHS Secretary Kennedy, Ag Secretary Rollins roll out action steps for national initiative on health.

Silencing one channel without building credible alternatives risks leaving patients less informed and physicians more burdened.

A three-part webinar series, starting on Sept. 10, will bring together legal, policy and industry leaders to dissect the high-stakes implications of the MFN initiative for pharma, payers and patients.

New position paper outlines scope of problem and offers policies that could help.

Study examines potential harm to market competition by pharmacy benefit managers and health insurers.

The President shared letters to pharma CEOs on Truth Social Thursday, giving them 60 days to match U.S. drug prices to the lowest rates in other wealthy nations.

Synthetic opioid sold at stores and online is ‘a recipe for a public health disaster.’

Consumer and patient protections are in two bills that have support of doctors in Congress.

Why lower-cost alternatives struggle to gain ground

New report identifies ‘misalignment’ between research spending and chronic diseases that affect millions of people.

New tariffs of up to 200% could hit medications from the European Union and beyond, raising alarms over affordability, access and supply for physicians and patients.

FDA also publishes review letters in new drug approval process.

A review of more than 400,000 patients shows deprescribing works to reduce medication overload in overload adults, but effects on hospital visits and death are less clear.

If we want to remain the global leader in innovation, we need to keep a strong pricing system at home and use trade deals to push our allies to pay their fair share for the medical advances they rely on.

Out-of-pocket caps protect high spenders, but many others could see their drug costs rise.

Despite advocates and state actions, hard evidence is scant and there is no national consensus that cannabis is a medical treatment, scholars say.

Under new legislation, patients would get far fewer suggestions to ‘ask your doctor if…’

Experts examine drug pricing policies and potential effects of new tariffs on imports.

Medical groups warn of eroding trust, reduced access and insurance fallout after HHS bypasses expert vaccine advisory panel.

As digital clinics race to capitalize on the GLP-1 weight loss boom, concerns grow over quality, safety and the erosion of patient-centered care.

HHS announces plan to create ‘most-favored-nation’ cost scale so U.S. is not subsidizing drug prices in other countries.

‘Wild west’ of pharmaceutical sales developed as patients clamor for GLP-1s for obesity treatment.

Novavax continues working with FDA, but case could signal a shift in broader vaccine procedures.

Moves prompt praise from opponents of high costs of medications, PBMs.

Are your patients' medications about to get more expensive?

As obesity medications gain popularity, many older Americans support coverage — but not higher premiums.

Policy center argues patients around the world benefit when Americans pay more than their fair share for research and medicines.

HELP Committee Senators press Trump’s FDA pick on the cancelled vaccine advisory meeting, mifepristone access, transparency and agency layoffs.